The Use of CellCollector Assay to Detect Free Cancer Cells in the Peritoneal Cavity of Colorectal Cancer Patients: An Experimental Study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70378 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yudi Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Sensitivity and Specificity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) is associated with high incidence and mortality rates globally. The presence of intraperitoneal free cancer cells (IFCCs) is recognized as an independent prognostic factor for CRC patients. However, a clinical gold standard for IFCCs detection is lacking. The GILUPI CellCollector has demonstrated high sensitivity and specificity in detecting free cancer cells, yet its application for CRC IFCCs detection remains unreported.
Methods
We selected CRC and normal cell lines to evaluate the CellCollector's ability to detect tumor cells. A total of 70 CRC patients and 17 patients with benign disease undergoing laparoscopic procedures were investigated. Peritoneal lavage fluid was collected pre‐ and post‐operation, and both real‐time PCR (CEA mRNA) and CellCollector detection were performed. We compared the sensitivity and specificity of these two methods.
Results
CellCollector can distinguish well between CRC and normal cells in cell line experiments. CellCollector detects IFCCs better than real‐time PCR (CEA) in CRC patients in different TNM Stages. The sensitivity of CellCollector was higher than that of real‐time PCR (84.6% vs. 48.4%), and the specificity of CellCollector was also higher than real‐time PCR (79.1% vs. 60.4%). There was no significant difference in the results of IFCCs detected by CellCollector before and after total mesorectal excision (TME) or complete mesocolic excision (CME) radical colorectomy ( p > 0.05), but there was a significant difference in real‐time PCR detection ( p < 0.05).
Conclusions
The CellCollector demonstrates superior sensitivity and specificity compared to real‐time PCR for detecting IFCCs in CRC patients, suggesting its potential as a clinical tool for IFCCs detection. Trial Registration ClinicalTrials.gov identifier: NCT01978444
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
- GI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Xiangshang Xu, Jianping Gong
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Wu, Y., He, F., Liu, L., Jiang, W., Deng, J., Zhang, Y., Cao, Z., Xu, X., & Gong, J. (2024). The Use of CellCollector Assay to Detect Free Cancer Cells in the Peritoneal Cavity of Colorectal Cancer Patients: An Experimental Study. Cancer Medicine. https://doi.org/10.1002/cam4.70378
Vancouver
Wu Y, He F, Liu L, Jiang W, Deng J, Zhang Y, et al. The Use of CellCollector Assay to Detect Free Cancer Cells in the Peritoneal Cavity of Colorectal Cancer Patients: An Experimental Study. Cancer Medicine. 2024. doi:10.1002/cam4.70378
BibTeX
@article{Wu2024,
author = {Wu, Yudi and He, Fangxun and Liu, Liang and Jiang, Wei and Deng, Jiao and Zhang, Yujie and Cao, Zhixin and Xu, Xiangshang and Gong, Jianping},
title = {The Use of CellCollector Assay to Detect Free Cancer Cells in the Peritoneal Cavity of Colorectal Cancer Patients: An Experimental Study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70378}
}
EUVIMED